Keyphrases
Cervical Cancer Screening
100%
Cervical Cancer
56%
Finland
47%
Screening Program
39%
Human Papillomavirus Testing
38%
Cervical Intraepithelial Neoplasia
37%
High-risk Human Papillomavirus (HR-HPV)
34%
Colposcopy
30%
CIN3+
29%
Organized Screening Program
24%
Triage
23%
Randomized Setting
22%
Confidence Interval
20%
Conventional Cytology
20%
Human Papillomavirus DNA
19%
Cytological Screening
19%
Intraepithelial Neoplasia
19%
Randomized Evaluation
19%
Prospective Cohort Study
18%
Evaluation Trial
18%
DNA Testing
17%
Detection Rate
15%
Screening Test
14%
Relative Risk
12%
Routine Screening
11%
Organized Screening
11%
Oncogenic Human Papillomavirus
10%
Cytological Diagnosis
10%
Randomized Design
10%
CIN2+
9%
Cervical Intraepithelial Neoplasia Grade 3
9%
Quality of Life
9%
Intraepithelial Adenocarcinoma
9%
Performance Variation
9%
Adjunction
9%
Local Excision
9%
Overtreatment
9%
Cancer Pattern
9%
Electrical Impedance Spectroscopy
9%
Regional Screening
9%
Primary HPV Screening
9%
Papillomavirus Infections
9%
First-degree Relatives
9%
Screening Population
9%
Age-specific
9%
Long-run Risk
9%
Ovarian Cancer Patients
9%
Alternative Technology
9%
Ovarian Cancer
9%
LLETZ
9%
Medicine and Dentistry
Cervical Cancer
88%
Screening
81%
Cytotechnology
63%
Wart Virus
59%
Cervical Cancer Screening
54%
Cervical Intraepithelial Neoplasia
40%
Arm
34%
Colposcopy
27%
Triage
26%
Patient Referral
19%
Intraepithelial Neoplasia
19%
Cervical Screening
19%
False Negative Result
18%
Malignant Neoplasm
16%
Screening Test
15%
DNA Screening
14%
Reproducibility
11%
Health Care Cost
10%
Cancer Incidence
10%
Biopsy Technique
10%
Prevalence
9%
Prospective Cohort Study
9%
Adenocarcinoma in Situ
9%
Quality of Life
9%
Mass Screening
9%
Local Excision
9%
Public Health
9%
Cancer Epidemiology
9%
Krukenberg Tumor
9%
Papillomavirus Infection
9%
Ovarian Cancer
9%
Cohort Analysis
9%
Cancer Registry
8%
Precancerous Condition
8%
Diseases
5%
Program Effectiveness
5%
